DXCM - DexCom - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2521311074

Continuous Glucose Monitoring Systems, Diabetes Management Tools

DexCom, Inc. is a medical device company that specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers worldwide.

Their innovative products include the Dexcom G6 and Dexcom G7, which are integrated CGM systems that help manage diabetes. These systems provide real-time glucose levels, trends, and alerts, empowering individuals to make informed decisions about their diabetes treatment.

In addition to their CGM systems, DexCom offers Dexcom Share, a remote monitoring system that allows users to share their glucose data with healthcare providers, caregivers, or loved ones. This feature enables real-time monitoring and timely interventions, improving diabetes management and overall health outcomes.

The company has also developed the Dexcom Real-Time API, which allows authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This integration enables a more comprehensive and connected diabetes management ecosystem.

DexCom's product portfolio also includes Dexcom ONE, a system designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has also submitted the Dexcom Stelo for FDA review, which is specifically designed for people with type 2 diabetes.

DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop innovative blood-based or interstitial glucose monitoring products. This partnership aims to advance glucose monitoring technology and improve diabetes care.

The company markets its products directly to endocrinologists, physicians, and diabetes educators, ensuring that healthcare professionals have access to the latest CGM technology and can provide optimal care for their patients.

Founded in 1999, DexCom is headquartered in San Diego, California, and has established itself as a leader in the diabetes management industry. For more information, visit their website at https://www.dexcom.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for DXCM - DexCom  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for DXCM - DexCom  - Stock Price & Dividends

DXCM Stock Overview

Market Cap in USD 45,360m
Sector Healthcare
Industry Medical Devices
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 2005-04-14

DXCM Stock Ratings

Growth 5y 53.8
Fundamental 77.3
Dividend -
Rel. Performance vs Sector -1.67
Analysts 4.44/5
Fair Price Momentum 102.99 USD
Fair Price DCF 38.68 USD

DXCM Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

DXCM Growth Ratios

Growth 12m -16.94%
Growth Correlation 12m 26%
Growth Correlation 3m -70%
CAGR 5y 24.67%
CAGR/Mean DD 5y 1.16
Sharpe Ratio 12m -0.55
Alpha vs SP500 12m -46.30
Beta vs SP500 5y weekly 1.14
ValueRay RSI 54.26
Volatility GJR Garch 1y 40.65%
Price / SMA 50 -4.99%
Price / SMA 200 -2.7%
Current Volume 2300.4k
Average Volume 20d 2707.9k

External Links for DXCM Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of DXCM stocks?
As of July 14, 2024, the stock is trading at USD 114.06 with a total of 2,300,403 shares traded.
Over the past week, the price has changed by +0.33%, over one month by -2.68%, over three months by -16.22% and over the past year by -17.02%.
What are the forecast for DXCM stock price target?
According to ValueRays Forecast Model, DXCM DexCom will be worth about 114.6 in July 2025. The stock is currently trading at 114.06. This means that the stock has a potential upside of +0.46%.
Issuer Forecast Upside
Wallstreet Target Price 152.1 33.3
Analysts Target Price 137 20.1
ValueRay Target Price 114.6 0.46